Additionally, ARO-HSD (GSK4532990), a siRNA that completed Phase 1 trials (NCT04202354), showed good tolerance and reduced HSD17B13 expression and serum ALT levels in patients with MASH [126]. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatohepatitis.